

Quarterly activities report for January – March 2025

The quarterly activities include details of monitoring and compliance activities by the Office of the Gene Technology Regulator (OGTR) during the quarter.

Monitoring of GMO Dealings involving Intentional Release (DIR)

During the quarter, the OGTR did not inspect any GM plant field trial sites. The OGTR inspected **one** organisation conducting GMO dealings involving intentional release relating to protein fermentation and production.

Table 1 – Summary of inspection activities of DIR licences for the January – March 2025 quarter.

Licence holder	Licence Number
Cauldron Molecules Pty Ltd	DIR-200

Monitoring of GMO Dealings Not involving Intentional Release (DNIR), certified facilities and DIR clinical trials

During the quarter, the OGTR inspected **six** organisations holding certified facilities (**Table 2**), **two** of which were also undertaking GMO dealings authorised by a DNIR licence (**Table 3**).

Table 2 – Summary of organisations and facility types that the OGTR inspected for the January – March 2025 quarter.

Organisation	Physical Containment (PC) level	Number of facilities monitored
University of Tasmania	PC2 Laboratory	1
	PC2 Animal Facility	2
	PC2 Aquatic	1
	PC2 Invertebrate	1
	PC2 Plant Facility	3
The Walter and Eliza Hall Institute of Medical Research (WEHI)	PC2 Laboratory	5
	PC2 Animal Facility	1
	PC2 Invertebrate	1
University of New South Wales	PC2 Laboratory	11
	PC2 Animal Facility	1

Organisation	Physical Containment (PC) level	Number of facilities monitored
Griffith University	PC2 Laboratory	3
	PC2 Animal Facility	1
	PC3 Laboratory	1
	PC3 Animal Facility	1
QIMR Berghofer	PC2 Laboratory	10
	PC2 Invertebrate	1
	PC2 Aquatic	1
Royal Brisbane and Women's Hospital	PC2 Laboratory	1
	PC2 Animal	1
Total		47

Table 3 – Summary of inspection activities for DNIR licences for the January – March 2025 quarter.

Licence holder	Licence number
Griffith University	DNIR-617
The Walter and Eliza Hall Institute of Medical Research (WEHI)	DNIR-649

Practice Reviews, Audits and Investigations

The Monitoring and Compliance section may initiate Practice Reviews in response to observations made during earlier monitoring activities, or to follow up incident reports. The objective is to determine if licence conditions can be, and are being, effectively implemented.

During the January – March 2025 quarter, the OGTR continued its program of practice reviews, undertaking meetings with:

- The University of Tasmania (DIR-195) - Trial of a genetically modified vaccine against devil facial tumour disease in Tasmanian devils, as part of the practice review into the '*Preparedness of accredited organisations to undertake licensed dealings involving intentional release*'.

During the January – March 2025 quarter the OGTR continued an audit of Monash University in Victoria.

Audit findings will be reported in the Gene Technology Regulator's Annual Report once the respective audit has been completed.

Audits of seed breeding companies were conducted in Queensland reviewing their quality assurance processes as part of the OGTR Low Level Presence Strategy. These audits of the industry are ongoing and will be reported in the Annual Report.

During the January – March 2025 quarter the OGTR did not commence any investigations.

Monitoring and Compliance Findings

Findings from routine monitoring, auditing, investigations, and related enforcement activities, will be provided in the Regulator's Annual Report in accordance with section 136 of the *Gene Technology Act 2000*.